Thromb Haemost 1970; 24(01/02): 265-272
DOI: 10.1055/s-0038-1654233
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Studies on the Anticoagulant Action of Aprotinin (“Trasylol”)[*]

C. R. M Prentice M. R. C. P.
1   University Department of Medicine, Royal Infirmary, Glasgow, C.4
,
G. P McNicol M. D., Ph. D., F. R. C. P. (Ed., Glasgow)
1   University Department of Medicine, Royal Infirmary, Glasgow, C.4
,
A. S Douglas M. D., F. R. C. P. (Lond., Ed., Glasg.)
1   University Department of Medicine, Royal Infirmary, Glasgow, C.4
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Preview

Summary

Studies were undertaken to localize the site of the anticoagulant action of Aprotinin (“Trasylol”). Contact activation studies using either kaolin or contact product eluted from celite demonstrated that Aprotinin had greatest inhibitory action against the interaction of a surface with the contact factors, but some inhibition of formed contact product was also noted. In addition, Aprotinin was found to have a slight anticoagulant action against activated factor IX prepared by incubation of contact product with a calcium phosphate eluate from serum. No inhibitory action in pharmacological doses was demonstrated against activated factor X or later stages in the coagulation sequence.

It was concluded that Aprotinin is a relatively weak anticoagulant in doses liable to be obtained in vivo during therapeutic infusions.

* The work conducted by C.R. M. Prentice has been supported by a grant from the Medical Research Council.